Second Primary Malignancies (SPMs) in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With the Combination of a Targeted Agent With an Antibody in 4 Phase 2 Trials of the German CLL Study Group (GCLLSG)

被引：0
|
作者：
Goergen, Ellinor [1 ,2 ]
von Tresckow, Julia [3 ]
Giza, Adam [1 ,2 ]
Robrecht, Sandra [1 ,2 ]
Fink, Anna-Maria [1 ,2 ]
Fischer, Kirsten [1 ,2 ]
Al-Sawaf, Othman [1 ,2 ]
Fuerstenau, Moritz [1 ,2 ]
Simon, Florian [1 ,2 ]
Kutsch, Nadine [1 ,2 ]
Nieper, Pascal [1 ,2 ]
Tausch, Eugen [4 ]
Ritgen, Matthias [5 ]
Boettcher, Sebastian
Kreuzer, Karl-Anton [1 ,2 ]
Stilgenbauer, Stephan [4 ,6 ]
Langerbeins, Petra [1 ,2 ]
Eichhorst, Barbara [1 ,2 ]
Hallek, Michael [1 ,2 ]
Cramer, Paula [1 ,2 ]
机构：
[1] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[2] Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, German CLL Study Grp, Cologne, Germany
[3] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Clin Hematol & Stem Cell Transplantat, Essen, Germany
[4] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany
[5] Univ Schleswig Holstein, Dept Internal Med 2, Campus Kiel, Kiel, Germany
[6] Univ Rostock, Clin Hematol Oncol & Palliat Med 3, Rostock, Germany
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
CLL; second primary malignancies; obinutuzumab; ibrutinib; venetoclax; Phase; 2;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-465
引用
收藏
页码：S354 / S355
页数：2
相关论文
共 50 条
  • [41] First line therapy of patients (pts) with advanced chronic lymphocytic leukemia (CLL) older than 65 years with fludarabine versus chlorambucil: Interim analysis of a phase III study of the German CLL Study Group (GCLLSG).
    Schmitt, BF
    Kneba, M
    Ritgen, M
    Stauch, M
    Emmerich, B
    Bergmann, M
    Busch, R
    Wendtner, CM
    Hallek, M
    BLOOD, 2002, 100 (11) : 387A - 387A
  • [42] Outcomes and Treatment Sequences of Therapies with BCL2-and BTK Inhibitors in Chronic Lymphocytic Leukemia (CLL): An Analysis of Patient Data within the German CLL Study Group (GCLLSG) Registry
    Kutsch, Nadine
    Ligtvoet, Rudy
    Robrecht, Sandra
    Linde, Hartmut
    Illmer, Thomas
    Doerfel, Steffen
    Lipke, Joerg
    Aldaoud, Ali
    Schlag, Rudolf
    Dengler, Jolanta
    Al-Sawaf, Othman
    Langerbeins, Petra
    Cramer, Paula
    Eichhorst, Barbara F.
    Hallek, Michael
    Fischer, Kirsten
    Fink, Anna Maria
    BLOOD, 2023, 142
  • [43] Severe hematological and non-hematological toxicity but good efficacy of bendamustine in pretreated patients with relapsed or progressive chronic lymphocytic leukemia (CLL) - Preliminary results of a phase I study of the German CLL Study Group (GCLLSG).
    Bergmann, M
    Herold, M
    Emmerich, B
    Boening, L
    Wilhelm, M
    Hallek, M
    BLOOD, 2001, 98 (11) : 288B - 289B
  • [44] Chemoimmunotherapies prolong overall survival in patients with chronic lymphocytic leukemia irrespective of time point of administration - results of a metaanalysis of the German CLL Study Group (GCLLSG)
    Isfort, S. T.
    Cramer, P.
    Bahlo, J.
    Busch, R.
    Fink, A. -M
    Langerbeins, P.
    Goede, V
    Elter, T.
    Bergmann, M.
    Stauch, M.
    Stilgenbauer, S.
    Wendtner, C.
    Eichhorst, B.
    Fischer, K.
    Hallek, M.
    ONKOLOGIE, 2012, 35 : 99 - 99
  • [45] A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)
    Chen, Christine I.
    Snitzler, Susi
    Levina, Olga
    Wang, Tong
    Le, Lisa W.
    Paul, Harminder
    Wei, Ellen Nong
    Lau, Anthea
    Queau, Michelle
    Johnston, James B.
    Trudel, Suzanne
    Smith, Deborah A.
    BLOOD, 2015, 126 (23)
  • [46] The Performance of Computed Tomography (CT) Scans or Ultrasound Has No Clinical Relevance in Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Metaanalysis from Three Phase III Studies of the German CLL Study Group (GCLLSG).
    Eichhorst, Barbara F.
    Fischer, Kirsten
    Fink, Anna-Maria
    Elter, Thomas
    Wendtner, Clemens M.
    Busch, Raymonde
    Hallek, Michael
    BLOOD, 2008, 112 (11) : 385 - 386
  • [47] Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group
    Cramer, Paula
    Fink, Anna-Maria
    Busch, Raymonde
    Eichhorst, Barbara
    Wendtner, Clemens-Martin
    Pflug, Natali
    Langerbeins, Petra
    Bahlo, Jasmin
    Goede, Valentin
    Schubert, Friederike
    Doehner, Hartmut
    Stilgenbauer, Stephan
    Dreger, Peter
    Kneba, Michael
    Boettcher, Sebastian
    Mayer, Jiri
    Hallek, Michael
    Fischer, Kirsten
    LEUKEMIA & LYMPHOMA, 2013, 54 (08) : 1821 - 1822
  • [48] Comparison of the efficacy and toxicity of fludarabine (F) in first line therapy of younger versus elderly patients (Pts) with advanced chronic lymphocytic leukemia (CLL): Results of a meta-analysis of two phase III trials of the German CLL study group (GCLLSG).
    Eichhorst, BF
    Busch, R
    Wendtner, CM
    Hallek, M
    BLOOD, 2005, 106 (11) : 213A - 213A
  • [49] Phase-II-study of rituximab in combination with fludarabine in patients (pts) with chronic lymphocytic leukemia (CLL).
    Schulz, H
    Klein, SK
    Rehwald, U
    Reiser, M
    Ibach, S
    Aulitzky, WE
    Hensel, M
    Herold, M
    Huhn, D
    Knauf, U
    Hallek, M
    Diehl, V
    Engert, A
    BLOOD, 2001, 98 (11) : 364A - 364A
  • [50] Fludarabine (F) induces higher response rates in first line therapy of older patients (pts) with advanced chronic lymphocytic leukemia (CLL) than chlorambucil:: Interim analysis of a phase III study of the German CLL study group (GCLLSG).
    Eichhorst, BF
    Busch, R
    Stauch, M
    Kneba, M
    Ritgen, M
    Söling, U
    Burkhard, O
    Bergmann, M
    Wendtner, CM
    Hiddemann, W
    Emmerich, B
    Hallek, M
    BLOOD, 2003, 102 (11) : 109A - 109A
12345